VYNE Therapeutics
Update in progressVYNE (NCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
VYNE Therapeutics is a clinical‑stage biopharmaceutical company developing therapies for chronic inflammatory and immune‑mediated diseases. Its lead program, repibresib gel (VYN201), is a topically applied soft drug BET inhibitor designed to reduce inflammation with low systemic exposure. VYN202 is a BD2‑selective oral BET inhibitor in Phase 1b for immune‑mediated conditions. Founded 2003, Stewartsville, New Jersey; formerly Menlo Therapeutics (renamed 2020).
Company score
- Sentiment
- 0.16
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.16
- Governance
- 0.04
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.06
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNCM
- LocationUnited States
- CEOMr. David T. Domzalski
- Founded2003
- Employees10
- Websitevynetherapeutics.com
Identifiers
- ISINUS92941V2097
- FIGIBBG00H5W8GM8
- CUSIP92941V209
- CIK0001566044